Furstenau M, Giza A, Weiss J, Kleinert F, et al. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood 2024;144:272-282.
PMID: 38620072